Creative Biolabs has extensive experience in drug discovery. We offer you the best advice and support to advance your programs. With our advanced platform, Creative Biolabs is confident in offering the best services to meet our customers' specific demands.
Ankylosing spondylitis (AS), the most frequent subtype of spondyloarthritides (SpA), is a chronic, immune-mediated inflammatory disease with severe courses. AS is characterized by inflammatory back pain, frequently associated with arthritis and enthesitis. Inflammation processes associated with AS can lead to bone erosion, new bone formation, and ankylosis occurring in the spine, which leads to severe pain, a reduction in spinal mobility and stiffness. AS starts commonly early in life, between 20 and 30 years in most cases, leads to progressive, severe functional impairment, and reduces the quality of life.
Therapeutic options for patients with AS have been rather limited in recent decades and current drug therapy options are focused on reducing inflammation, stiffness, back pain, and disability. These traditional treatments include nonsteroidal anti-inflammatory drugs (NSAIDs), anti-rheumatic drugs (DMARDs), and physical therapy. Despite these therapies reducing inflammation and improving clinical manifestations, many patients with AS suffer from unresponsive or unbearable side effects from the drugs.
Given the reported efficacy and success of biological therapies, a considerable proportion of patients with AS may well benefit from the new biological therapies, particularly anti-tumor necrosis factor (TNF). Recently, there is accumulating evidence that TNF blocking agents is highly effective in relieving symptoms and in reducing spinal inflammation. The main monoclonal antibody agents targeting TNF-α have proven clinical efficacy in patients with active AS. The use of TNF-α inhibitors could be the best choice for patients who poorly respond to former treatments.
Mesenchymal stem cell therapy (MSCT) has the promise to raise hope as a favorable therapeutic choice in treating immune-mediated disorders such as AS. Mesenchymal stem cells (MSCs) with substantial immunomodulatory and regenerative properties can migrate chemotactically to the site of inflammation and injury and attenuate the inflammatory responses to help tissue repair. Previous studies have shown that injection of MSCs might be beneficial in alleviating AS signs and symptoms. The results of these studies would pave the way for developing efficient methods of cell therapy to improve the treatment of AS in the future.
Advances in understanding the pathogenesis of AS have raised the possibility of substantial improvements in the treatment of AS. Creative Biolabs has made a long-term commitment to the discovery and development of AS drugs for our customers all over the world. To bring our customers impeccable service of drug development, our seasoned scientific team has developed several solutions to meet our customers' different requirements, including but not limited to:
Researchers from Creative Biolabs have earned a great reputation from our clients for superior custom drug development services. Based on our vast experience and solid technical strength, we will accelerate the development and potential application of AS drug discovery programs and guarantee the finest results for our customers all over the world. Please feel free to contact us to let us know how we can help with your projects.
For Research Use Only | Not For Clinical Use
Contact us
USA
Creative Biolabs is a world-leading CRO that is skilled in developing novel therapies,
especially in antibody and cell therapy for autoimmune diseases.
Copyright © 2024 Creative Biolabs. All Rights Reserved.
